Navigation Links
New Study Suggests Cholesterol-Lowering Statins Reduce Severe Asthma Attacks that Result in Hospitalizations and Emergency Room Visits
Date:3/14/2009

Patients on corticosteroids are one-third less likely to need emergency room treatment or hospitalization when also taking statin medications

Study is first in a series to examine factors impacting patient response to asthma medications

FRANKLIN LAKES, N.J., March 14 /PRNewswire-FirstCall/ -- Results of a new study presented at the 2009 Annual Meeting of the American Academy of Asthma, Allergy and Immunology (AAAAI) show dramatic reductions in emergency room (ER) visits and hospitalizations for asthma patients taking cholesterol-lowering statins in addition to common asthma treatments. The study was jointly conducted by researchers from Medco Health Solutions, Inc. (NYSE: MHS) and Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School.

In the first and largest investigation of statin effects on clinical outcomes in humans with asthma, researchers found that among adult patients on inhaled corticosteroids, those also taking statins reduced their odds of an asthma-related hospitalization or ER visit by 33 percent.

"The implications of this study are exciting because they point to the potential role statins could play in helping prevent the most serious asthma attacks that land patients in the hospital," said Dr. Robert Epstein, Medco's chief medical officer and one of the study authors. "There has been heightened interest in how the anti-inflammatory power of statins might benefit asthma patients and a number of animal studies have shown encouraging results. While the findings of this patient study should be considered preliminary and further clinical studies will be needed to draw any conclusions about care, they do show promise for the use of statins in asthma treatment. To that end, there are currently a number of prospective studies on this topic underway that
'/>"/>

SOURCE Medco Health Solutions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...sreal, December 2 Cardio...g developer of advanced,cardiovascular surgery tec...of Directors approved a one-for-three forward stoc...to Cardio Vascular Medical Device shareholders. ,...he estimated date the stock,split will be payable ...
(Date:12/2/2009)...., Dec. 2 Roche (SIX: RO...ed States Food & Drug Administration (FDA) app...nucleic acid test, to screen source plasma in pool...test, called the cobas® TaqScreen MPX Test fo...e, in-vitro test for the simultaneous, direct dete...
(Date:12/2/2009)...VER, N.J., Dec. 2 Novartis announc...presentation on Tasigna® (nilotinib) 200 mg c...onstrate the strength of the company,s hematology ..., The new data, at the 51st American Society of He...light the company,s current therapies and investig...
Breaking Medicine Technology:Cardio Vascular Medical Device Announces Forward Stock Split 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Advance in bowel cancer test research 48298 1Discovery raises new doubts about dinosaur bird links 8763 1Discovery raises new doubts about dinosaur bird links 8763 2Discovery raises new doubts about dinosaur bird links 8763 3Morphotek 28R 29 Inc Announces FDA Acceptance of Investigational New Drug Application for MORAb 004 a Monoclonal Antibody for the Treatment of Soli 48291 1Morphotek 28R 29 Inc Announces FDA Acceptance of Investigational New Drug Application for MORAb 004 a Monoclonal Antibody for the Treatment of Soli 48291 2Morphotek 28R 29 Inc Announces FDA Acceptance of Investigational New Drug Application for MORAb 004 a Monoclonal Antibody for the Treatment of Soli 48291 3
...eters of Sleep Maintenance - - Pha... 12 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) a...Hospital presented data from Arena,s positive Phas... insomnia in an oral presentation at the SLEEP,200...al Sleep Societies in,Baltimore, Maryland., APD12...
...Advancing Second-Generation ... June 12 ChemoCentryx, Inc.,today announced the c...pany,s PROTECT-1 (the Prospective Randomized Oral ...ase II/III clinical trial of Traficet-EN(TM),(CCX2...disease. This,innovative clinical trial comprises ...
Other Medicine Technology:Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 2Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 3Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 4Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 5Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 6ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 2ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 3ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 4ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 5ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 6
(Date:12/2/2009)...te cancer patients who have a prostate-specific an...two years after external beam radiation therapy (E...nd cancer-related death, according to a study in t...f Radiation Oncology*Biology*Physics, the official...ology (ASTRO)., PSA levels in a prostate cancer ...
(Date:12/2/2009)...DRIA, VA Constraint-induced movement therapy (CIM... for children with hemiplegic cerebral palsy, but ...atic review published in the November issue of Ph...he American Physical Therapy Association (APTA). T...and 2 systematic reviews, concluded that further r...
(Date:12/2/2009)... AB First Aid has been a top name...on in 1980. With quality products, professional st...t aid supplies, AB First Aid has established itsel...mbulance care, and as a first aid supplies distrib...iness is about to enter into its next phase with t...
(Date:12/2/2009)... National Race Series to increase...their families on the importance of early detectio...cember 2, 2009 -- Men, women, families, friends an...are invited to participate in the Rudolph Ramble 5...l PACE Race Series , which was launched by the P...
(Date:12/2/2009)... A team of Kendall Hunt authors e... Year Award at the recent National Association for...Louis, November 5-7, 2009. , ... of Kendall Hunt authors earned the 2009 Gifted Ch...t National Association for Gifted Children’s...
Breaking Medicine News(10 mins):Health News:PSA value at 2 years post-treatment can predict long-term survival in prostate cancer patients 2Health News:Report shows CIMT may improve arm use in children with hemiplegic cerebral palsy 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 3Health News:PACE Race Returns with Denver's Rudolph Ramble 2Health News:PACE Race Returns with Denver's Rudolph Ramble 3Health News:PACE Race Returns with Denver's Rudolph Ramble 4Health News:Kendall Hunt Authors Earn NAGC “Paper of the Year” Award 2
... ABBOTT PARK, Ill., Jan. 21 Abbott ( NYSE: ...urth quarter ended Dec. 31, 2008. , , -- Dil..., were $1.06, reflecting 14.0 percent gro...e $0.98, up 27.3 percent., -- Worldwide sale...
... Company,s SAM1600 Family of Analog to Digital Con...ved Electronic Products, Product of The Year Award...ression Technology Named EDN Hot 100 Products of 2...ased to announce it has received top honors from i...
... For the first quarter of...ed rates on their Spanish translation services. On...marketing agencies in the United States, Auerbach ... -- Auerbach International Inc., one of the foremo...
... My1Stop.com, the eco fri...n Business Alliance® to provide customers with...tomers receive a 10% discount when using "My1...Stop.com, the eco friendly printing superstore, ha...
... In 2007, South Africa,s new Children,s Act came ...a host of rights relating to reproductive health, ...t policies allow individual schools to decide whet...h. , Juliana Han (Harvard Law School, Cambridge, ...
... , AIM and MedEmerg Combine to Form One of the ...anada, , , TORONTO, Jan. 20 /PRNewswire-FirstCall...ully integrated health care company, and Med-Emerg...viously disclosed all-stock merger transaction. Th...
Other Medicine News:Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 2Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 3Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 4Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 5Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 6Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 7Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 8Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 9Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 10Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 11Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 12Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 13Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 14Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 15Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 16Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 17Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 18Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 19Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 20Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 21Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 22Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 23Health News:Samplify Systems Receives Top Honors From Electronic Products and EDN Magazines 2Health News:Samplify Systems Receives Top Honors From Electronic Products and EDN Magazines 3Health News:Spanish On-Sale: Auerbach International Offers Discounted Rates for Spanish Translations 2Health News:Spanish On-Sale: Auerbach International Offers Discounted Rates for Spanish Translations 3Health News:My1Stop.com Partners with Green Business Alliance to Help Customers Go Green 2Health News:South African policy on adolescents' rights to access condoms is causing confusion 2Health News:AIM Health Group Inc. and Med-Emerg International Inc. Announce Completion of Previously Disclosed Merger Transaction 2Health News:AIM Health Group Inc. and Med-Emerg International Inc. Announce Completion of Previously Disclosed Merger Transaction 3Health News:AIM Health Group Inc. and Med-Emerg International Inc. Announce Completion of Previously Disclosed Merger Transaction 4Health News:AIM Health Group Inc. and Med-Emerg International Inc. Announce Completion of Previously Disclosed Merger Transaction 5Health News:AIM Health Group Inc. and Med-Emerg International Inc. Announce Completion of Previously Disclosed Merger Transaction 6
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
Medicine Products: